SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Piper Sandler from $12.00 to $22.00. They now have a "neutral" rating on the stock.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)